Whole Genome Sequencing Market Analysis

Whole Genome Sequencing Market Analysis

To get key market trends

  Download Free Sample

Based on the products & services, the global market is segmented into instruments, consumables, and services. The consumables segment accounted for majority revenue share in 2022 and is expected to reach USD 18.1 billion by 2032.
 

• This leading market share is due to the use of consumables in large quantities in every step of the sequencing process. Whether it's sample preparation, DNA extraction, amplification, or sequencing reactions, these consumables are essential, leading to significant sales volumes.
   
• Further, consumables are widely utilized in each sequencing run and each application might require specific consumables tailored to its needs. Therefore, laboratories and research institutions engaged in genomic research and diagnostics must continuously purchase these consumables to sustain their operations.
   
• Thus, this frequent repurchasing pattern ensures a steady revenue stream for companies commercializing these products, thereby contributing to the high segment demand.

Based on the type, the global whole genome sequencing market is classified into large whole genome sequencing and small whole genome sequencing. The large whole genome sequencing segment dominated the market with 63.2% revenue share in 2022. There is a growing focus on large whole genome sequencing technologies which aim to sequence the genomes of thousands or even millions of individuals. This contributes to population genomics research, allowing scientists to study genetic variations on a large scale and understand the genetic basis of diseases across different populations.
 

• Further, studying the genomes of large populations helps researchers understand genetic variations within and between populations. This knowledge is crucial for investigating and tracking population migrations and understanding human evolution.
   
• Moreover, various government initiatives, research organizations, and pharmaceutical companies invest in large-scale genomic research projects to identify potential drug targets and improve healthcare outcomes. Thus, all these factors will help to boost the growth of this segment.
   

Based on the technology, the whole genome sequencing market is classified into sanger sequencing, polymerase chain reaction, microarray, next generation sequencing and other technologies. The next generation sequencing segment dominated the market with 42.6% revenue share in 2022.
 

• There is a growing focus on Next-generation sequencing (NGS) technologies leading to their widespread adoption and prominence in genomic research and clinical applications. It can sequence millions of DNA fragments simultaneously. This high throughput significantly accelerates the sequencing process, enabling the rapid analysis of large genomes and multiple samples in a relatively short time.
   
• Also, high throughput is crucial for large-scale genomics projects, as these technologies drastically reduce the cost per base pair of sequencing compared to earlier methods. This cost-effectiveness makes genomic sequencing more accessible, allowing researchers and clinicians to conduct extensive sequencing projects within budget constraints.
   

Based on the application, the whole genome sequencing market is fragmented into diagnostics, drug discovery & development, precision medicine and other applications. In 2022, the drug discovery & development segment reached a market revenue of USD 1.9 billion. As identifying genes associated with diseases is a fundamental step in drug discovery, WGS helps researchers to identify disease-related genetic variations, mutations, and pathways, providing potential drug targets. Also, understanding the genetic basis of diseases facilitates the identification and validation of drug targets, guiding researchers toward proteins or pathways that can be modulated for therapeutic benefit.
 

Based on the end-user, the whole genome sequencing market is divided into hospitals & clinics, academic institutes & research centers, pharmaceutical & biotechnology companies, and other end-users. The academic and research institutes segment is expected to reach USD 12.4 billion by 2032. Academic and research institutes that offer whole genome sequencing services have several advantages, including:
 

• Whole genome sequencing delivers a comprehensive view of the entire genome, unlike focused approaches such as exome sequencing or targeted resequencing, which analyze a limited portion of the genome. This makes it ideal for discovery applications, such as identifying causative variants and novel genome assembly.
   
• Further, whole genome sequencing provides a high-resolution, base-by-base view of the genome, capturing both large and small variants that might be missed by other sequencing methods. Therefore, utilization of WGS in such institute will significantly contribute to the market growth.

 In 2022, the North American region dominated the global whole genome sequencing market with market revenue of 2.5 billion.
 

• The significant growth is majorly attributed to the increasing research institutions, universities, and medical centers in the region. These institutions have advanced research infrastructure, including cutting-edge sequencing technologies and skilled researchers, enabling significant contributions to genomics research.
   
• Additionally, the region hosts numerous leading biotechnology & pharmaceutical companies focused on genomics and personalized medicine. These companies invest significantly in genomic research and development, including large-scale sequencing projects. Therefore, this trend drives innovation in whole genome sequencing and its application in cancer treatments, thereby augmenting the regional market trends.